2nd Dec 2019 09:56
(Alliance News) - Pharmaceutical company Indivior PLC on Monday said new analysis from a year-long investigation of monthly Sublocade injection showed either improved or stable patient-centred outcomes versus placebo.
Sublocade injection is intended to treat patients with opioid use disorder who have already taken a medication containing active ingredient buprenorphine. The 12-month study looked at a number of outcome measures, including treatment effectiveness and improvement in the severity of addition as measured by a patient reported Addiction Severity Index.
Other measures included health and employment status, use of healthcare resources, and medication satisfaction. Study participants who were treated with Sublocade injection showed improved or maintained outcomes across these measures when compared to a placebo.
The analysis was published in the Journal of Substance Abuse Treatment. The drug is intended to be part of a treatment programme including counselling and psychosocial support.
Christian Heidbreder, Indivior's chief scientific officer, said: "These 12-month findings strengthen our original observations that previously showed that participants receiving Sublocade over a 6-month period reported better health, higher medication satisfaction, increased employment, and decreased healthcare utilization compared to placebo.
"These findings also show that patient-centred outcomes that can be measured during office visits may help clinicians assess their patient's improvement."
Shares in Indivior were up 0.4% at 40.70 pence in London on Monday morning.
By Anna Farley; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior